US pharmaceutical company Eli Lilly has great expectations for the drug candidate tirzepatide now that results from the firm's Surpass program are in.
In March, the firm presented data from a direct comparison study with the GLP-1 drug semaglutide from Danish company Novo Nordisk, which turned to the US firm's advantage.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.